Citi Boosts Eli Lilly with Buy Rating, Eyes Growth
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
- Latest
- Trending
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Investors can navigate Wells Fargo's stock amidst recent regulatory challenges with strategic insights for potential growth.
MicroStrategy buys 18,300 BTC for $1.1B, solidifying its position as the largest corporate Bitcoin holder.
United Airlines to offer free Starlink Wi-Fi on over 1,000 aircraft by 2025, enhancing passenger connectivity.
A security flaw in Apple's Vision Pro headset could infer data from gaze typing. It's patched in visionOS 1.3.
Monitor RH stock price levels at $300, $335, $400, and $430. Watch $280 during pullbacks after earnings exceeded expectations.
WebPT and Intel partner on AI motion capture for physical therapy, integrating RealSense technology into EMR for enhanced patient care.
Exploring Shiba Inu and GoodEgg's potential to rival Dogecoin in 2025's crypto market with innovative apps and community backing.
XRP and DOGE outperform as Bitcoin dips. Market sees drop in large transactions, indicating cautious big players.
The U.S. Commerce Department's AI proposal could increase compliance costs and shift the global AI landscape.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.